Pretreatment characteristics and treatment
| Characteristic . | . |
|---|---|
| Age (y) | |
| Median | 47 |
| Range | 17-81 |
| Sex [no. (%)] | |
| Male | 73 (54) |
| Female | 63 (46) |
| WBC (×109/L) | |
| Median | 18.6 |
| Range | 0.6-281.0 |
| BM blasts (%) | |
| Median | 74 |
| Range | 7-99 |
| FAB [no. (%)] | |
| M0 | 3 (2) |
| M1 | 17 (13) |
| M2 | 49 (36) |
| M3 | 16 (12) |
| M4 | 30 (22) |
| M5 | 14 (10) |
| M6 | 2 (1) |
| Unclassified | 5 (4) |
| CALGB treatment protocol [no. (%)] | |
| 8923 | 31 (23) |
| 9022 | 15 (11) |
| 9191 | 14 (10) |
| 9222 | 71 (52) |
| 9420 | 5 (4) |
| DFS | |
| Median | 8.6 mo |
| Range | 1 mo-4.7 y |
| Characteristic . | . |
|---|---|
| Age (y) | |
| Median | 47 |
| Range | 17-81 |
| Sex [no. (%)] | |
| Male | 73 (54) |
| Female | 63 (46) |
| WBC (×109/L) | |
| Median | 18.6 |
| Range | 0.6-281.0 |
| BM blasts (%) | |
| Median | 74 |
| Range | 7-99 |
| FAB [no. (%)] | |
| M0 | 3 (2) |
| M1 | 17 (13) |
| M2 | 49 (36) |
| M3 | 16 (12) |
| M4 | 30 (22) |
| M5 | 14 (10) |
| M6 | 2 (1) |
| Unclassified | 5 (4) |
| CALGB treatment protocol [no. (%)] | |
| 8923 | 31 (23) |
| 9022 | 15 (11) |
| 9191 | 14 (10) |
| 9222 | 71 (52) |
| 9420 | 5 (4) |
| DFS | |
| Median | 8.6 mo |
| Range | 1 mo-4.7 y |
WBC indicates white blood cells; BM, bone marrow; CALGB, Cancer and Leukemia Group B; DFS, disease-free survival.